RT Journal Article
SR Electronic
T1 A boost with SARS-CoV-2 BNT162b2 mRNA vaccine elicits strong humoral responses independently of the interval between the first two doses
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.04.18.22273967
DO 10.1101/2022.04.18.22273967
A1 Tauzin, Alexandra
A1 Gong, Shang Yu
A1 Painter, Mark M.
A1 Goel, Rishi R.
A1 Chatterjee, Debashree
A1 Beaudoin-Bussières, Guillaume
A1 Marchitto, Lorie
A1 Boutin, Marianne
A1 Laumaea, Annemarie
A1 Okeny, James
A1 Gendron-Lepage, Gabrielle
A1 Bourassa, Catherine
A1 Medjahed, Halima
A1 Goyette, Guillaume
A1 Williams, Justine C.
A1 Bo, Yuxia
A1 Gokool, Laurie
A1 Morrisseau, Chantal
A1 Arlotto, Pascale
A1 Bazin, Renée
A1 Fafard, Judith
A1 Tremblay, Cécile
A1 Kaufmann, Daniel E.
A1 De Serres, Gaston
A1 Côté, Marceline
A1 Duerr, Ralf
A1 Martel-Laferrière, Valérie
A1 Greenplate, Allison R.
A1 Wherry, E. John
A1 Finzi, Andrés
YR 2022
UL http://medrxiv.org/content/early/2022/04/18/2022.04.18.22273967.abstract
AB Due to the recrudescence of SARS-CoV-2 infections worldwide, mainly caused by Omicron BA.1 and BA.2 variants of concern, several jurisdictions are administering a mRNA vaccine boost. Here, we analyzed humoral responses induced after the second and third doses of mRNA vaccine in naïve and previously-infected donors who received their second dose with an extended 16-week interval. We observed that the extended interval elicited robust humoral responses against VOCs, but this response was significantly diminished 4 months after the second dose. Administering a boost to these individuals brought back the humoral responses to the same levels obtained after the extended second dose. Interestingly, we observed that administering a boost to individuals that initially received a short 3-4 weeks regimen elicited humoral responses similar to those elicited in the long interval regimen. Nevertheless, humoral responses elicited by the boost in naïve individuals did not reach those present in previously-infected vaccinated individuals.Competing Interest StatementA.R.G. is a consultant for Relation Therapeutics. E.J.W. is consulting for or is an advisor for Merck, Marengo, Janssen, Related Sciences, Synthekine, and Surface Oncology. E.J.W. is a founder of Surface Oncology, Danger Bio, and Arsenal Biosciences.Funding StatementThis work was supported by le Ministere de l Economie et de l Innovation du Quebec, Programme de soutien aux organismes de recherche et d innovation to A.F. and by the Fondation du CHUM. This work was also supported by a CIHR foundation grant #352417, by a CIHR operating Pandemic and Health Emergencies Research grant #177958, a CIHR stream 1 and 2 for SARS-CoV-2 Variant Research to A.F., and by an Exceptional Fund COVID-19 from the Canada Foundation for Innovation (CFI) #41027 to A.F. and D.E.K. Work on variants presented was also supported by the Sentinelle COVID Quebec network led by the LSPQ in collaboration with Fonds de Recherche du Quebec Sante (FRQS) to A.F. This work was also partially supported by a CIHR COVID-19 rapid response grant (OV3 170632) and CIHR stream 1 SARS-CoV-2 Variant Research to M.C. A.F. is the recipient of Canada Research Chair on Retroviral Entry no. RCHS0235 950-232424. M.C is a Tier II Canada Research Chair in Molecular Virology and Antiviral Therapeutics. V.M.L. is supported by a FRQS Junior 1 salary award. D.E.K is a FRQS Merit Research Scholar. G.B.B. is the recipient of an FRQS PhD fellowship. A.L. was supported by MITACS Acceleration postdoctoral fellowships. This work was also supported by NIH grants AI108545, AI155577, AI149680, and U19AI082630 (to E.J.W.), the University of Pennsylvania Perelman School of Medicine COVID Fund (to R.R.G. and E.J.W.); the University of Pennsylvania Perelman School of Medicine 21st Century Scholar Fund (to R.R.G.); and the Paul and Daisy Soros Fellowship for New Americans (to R.R.G).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All work was conducted in accordance with the Declaration of Helsinki in terms of informed consent and approval by an appropriate institutional board. Blood samples were obtained from donors who consented to participate in this research project at Centre Hospitalier de l Universite de Montreal (CHUM) and University of Pennsylvania. The study was approved by the respective Institutional Review Boards (no. 19.381 at CHUM and no 845061 at University of Pennsylvania)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript